Description

6-Chloro-4-(4-Fluoro-Phenyl)-4-Hydroxy-3-(2,2,2-Trifluoro-Ethyl)-3,4-Dihydro-1H-Quinazolin-2-One is a high-value, non-racemic synthetic intermediate of significant importance in modern pharmaceutical research and development. Its complex molecular architecture, featuring a chiral center and multiple halogen substituents, makes it a critical building block for constructing advanced active pharmaceutical ingredients (APIs). This compound is primarily sought after by research institutions and pharmaceutical companies engaged in the discovery and synthesis of novel therapeutic agents, particularly within central nervous system (CNS) and oncology drug pipelines.

Application

• Pharmaceutical Intermediate: A key chiral precursor in the multi-step synthesis of potent, targeted pharmaceutical compounds.
• Drug Discovery Research: Used in medicinal chemistry for structure-activity relationship (SAR) studies and lead optimization programs.
• API Synthesis: Serves as a core scaffold for the development of advanced Active Pharmaceutical Ingredients, especially in neurology and oncology.
• Chemical Reference Standard: Employed as a high-purity analytical standard for quality control and method development in regulatory submissions.
• Process Chemistry Development: Utilized for scaling up and optimizing synthetic routes from laboratory to pilot plant scale.
• Asymmetric Synthesis: Exploited for its chiral integrity in the synthesis of enantiomerically pure drug candidates.

Basic Information

Product Name	6-Chloro-4-(4-Fluoro-Phenyl)-4-Hydroxy-3-(2,2,2-Trifluoro-Ethyl)-3,4-Dihydro-1H-Quinazolin-2-One
CAS No.	910484-13-8
Molecular Formula	C₁₆H₁₁ClF₄N₂O₂
Molecular Weight	374.72 g/mol
Synonyms	6-Chloro-4-(4-fluorophenyl)-4-hydroxy-3-(2,2,2-trifluoroethyl)-3,4-dihydroquinazolin-2(1H)-one; (3R,4S)-6-Chloro-4-(4-fluorophenyl)-4-hydroxy-3-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-quinazolin-2-one; BMS-820836 Intermediate; BMS820836 Intermediate; Orexin-1 Receptor Antagonist Intermediate; DORA-1 Antagonist Intermediate; JNJ-54717793 Analog Intermediate; 910484-13-8
EINECS	Contact for details

Quality Control

Every batch of 6-Chloro-4-(4-Fluoro-Phenyl)-4-Hydroxy-3-(2,2,2-Trifluoro-Ethyl)-3,4-Dihydro-1H-Quinazolin-2-One is manufactured under strict quality management systems and undergoes comprehensive analytical testing. We ensure compliance with stringent internal specifications, which are aligned with ICH guidelines for pharmaceutical intermediates. A detailed Certificate of Analysis (COA) is provided with each shipment, confirming identity, purity, chiral purity, and impurity profile. Our quality commitment supports your regulatory filings and process validation requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (typically 15-25°C). The compound may be hygroscopic (moisture-sensitive); therefore, the container should be kept tightly sealed under an inert atmosphere if specified. Keep away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Chiral Purity (Chiral HPLC)	≥ 99.0% ee (specify enantiomer)
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.